Company intelligence / Profile preview

AcuRea

Palatine, Illinois, USA

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Acura Pharmaceuticals has several marketed products (e.g., OXAYDO® (oxycodone HCl), Nexafed®), and a pipeline of additional drug deterrence/abuse-resistant technologies. Their AVERSION® technology is licensed for approved and marketed drugs, while LIMITX™ is in development.

Therapeutic areas: NeurologyPulmonologyPsychiatry
Modalities: Small moleculeDrug delivery
Industry: Biotech

Partnerships

Zyla Life Sciences (for OXAYDO license)MainPointe Pharmaceuticals (Nexafed license)Abuse Deterrent Pharmaceuticals LLC (LTX-03 license)King Pharmaceuticals (opioid analgesic products)

Beyond the preview

Go deeper on AcuRea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcuRea.

Explore the full profile